Genomic Valley Biotech Limited (BOM:539206)
India · Delayed Price · Currency is INR 30.40
-0.09 (-0.30%)
At close: Aug 21, 2026
Genomic Valley Biotech Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 2.16 | 2.68 | 8.44 | 1.65 | 27.23 | 0.71 | |
Revenue Growth | -72.32% | -68.30% | 411.25% | -93.94% | 3758.23% | -66.09% |
Cost of Revenue | - | - | 2.02 | 0 | 15.86 | 0.02 |
Gross Profit | 2.16 | 2.68 | 6.42 | 1.65 | 11.37 | 0.68 |
Selling, General & Admin | 0.71 | 1.06 | 1.24 | 0.42 | 1.54 | 1.44 |
Other Operating Expenses | 1.1 | 1.18 | 0.79 | 1.06 | 1.04 | 2.44 |
Operating Expenses | 1.85 | 2.27 | 2.05 | 1.51 | 2.66 | 5.25 |
Operating Income | 0.3 | 0.4 | 4.37 | 0.14 | 8.71 | -4.56 |
Interest Expense | - | - | - | -0 | -0 | -0.43 |
Interest & Investment Income | - | - | 0.04 | 0 | 0.43 | 0.78 |
Other Non Operating Income (Expenses) | -0 | -0 | - | 0.01 | - | - |
EBT Excluding Unusual Items | 0.3 | 0.4 | 4.41 | 0.15 | 9.13 | -4.21 |
Other Unusual Items | - | - | - | - | -2.64 | 4.19 |
Pretax Income | 0.3 | 0.4 | 4.41 | 0.15 | 6.49 | -0.02 |
Income Tax Expense | 0.1 | 0.1 | 0.85 | -0 | 0.01 | 0.08 |
Net Income | 0.2 | 0.3 | 3.56 | 0.15 | 6.48 | -0.09 |
Net Income to Common | 0.2 | 0.3 | 3.56 | 0.15 | 6.48 | -0.09 |
Net Income Growth | -91.99% | -91.49% | 2245.53% | -97.66% | - | - |
Shares Outstanding (Basic) | 3 | 3 | 3 | 3 | 3 | 3 |
Shares Outstanding (Diluted) | 3 | 3 | 3 | 3 | 3 | 3 |
Shares Change | -2.08% | -0.43% | 0.24% | -0.70% | -1.79% | 1.91% |
EPS (Basic) | 0.07 | 0.10 | 1.17 | 0.05 | 2.12 | -0.03 |
EPS (Diluted) | 0.07 | 0.10 | 1.17 | 0.05 | 2.12 | -0.03 |
EPS Growth | -91.82% | -91.45% | 2240.00% | -97.64% | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | - | -0.19 | 0.18 | -0.2 | -7.79 | -21.29 |
Free Cash Flow Per Share | - | -0.06 | 0.06 | -0.07 | -2.55 | -6.84 |
Gross Margin | 100.00% | 100.00% | 76.08% | 99.78% | 41.75% | 96.53% |
Operating Margin | 13.92% | 14.97% | 51.78% | 8.56% | 31.99% | -646.85% |
Profit Margin | 9.40% | 11.33% | 42.19% | 9.20% | 23.81% | -13.24% |
Free Cash Flow Margin | - | -7.10% | 2.09% | -12.16% | -28.60% | -3017.82% |
EBITDA | 0.34 | 0.44 | 4.4 | 0.15 | 8.79 | -3.72 |
EBITDA Margin | 15.78% | 16.35% | 52.08% | 9.22% | 32.28% | - |
D&A For EBITDA | 0.04 | 0.04 | 0.03 | 0.01 | 0.08 | 0.84 |
EBIT | 0.3 | 0.4 | 4.37 | 0.14 | 8.71 | -4.56 |
EBIT Margin | 13.92% | 14.97% | 51.78% | 8.56% | 31.99% | - |
Effective Tax Rate | 32.45% | 24.32% | 19.33% | - | 0.09% | - |
Revenue as Reported | 2.16 | 2.68 | 8.48 | 1.67 | 27.65 | 1.55 |
Advertising Expenses | - | - | 0.03 | 0.04 | 0.04 | 0.04 |